Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$5.5MCash on Hand
4.3mo Cash Runway
Follow ENLV by emailGet an email when ENLV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ENLV, unsubscribe in one click. Privacy
📣 What ENLV Says Is Next
mid-2027 · Allocetra: “The trial is actively recruiting at clinical sites in the United States, Denmark and Poland, and the Company expects to report topline six-month data by mid-2027.”
Company press release, Oct 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Financing Enlivex entered a securities purchase agreement for a $7.5 million registered direct offering at $1.315 per share or pre-funded warrant plus an ordinary warrant, a 10.5% premium to the November 13, 2026 Nasdaq close. Form 6-K · SEC filing · Press release
Nov 2, 2026 ·
Clinical trial Enlivex reported 12-month topline data from its Phase IIa Allocetra trial in knee osteoarthritis patients aged 64+. Responders were 79.2% in the Allocetra group vs. 47.6% for placebo (p=0.027). Data will be presented at ACR Convergence on November 8, 2026. Form 6-K · SEC filing · Press release
Oct 28, 2026 ·
Clinical trial Enlivex has randomized 135 of a planned 182 patients in its Phase 2b trial of Allocetra for age-related knee osteoarthritis, with first injections administered at sites in the US and Europe. Topline six-month data are expected by mid-2027. Form 6-K · SEC filing · Press release
Oct 27, 2026 ·
Listing Enlivex received a Nasdaq delisting notice dated October 26, 2026, for failing the $1.00 minimum bid price over 30 business days to October 22, 2026. Because it effected a reverse split in the past 12 months, it gets no 180-day cure period. Form 6-K · SEC filing · Press release
Oct 22, 2026 ·
Listing Shareholders approved reverse share splits at an October 22, 2026 meeting. The Board set a 1-for-16 reverse split effective October 27, 2026, reducing outstanding ordinary shares from 24,511,905 to approximately 1,531,995. Fractional shares will be rounded up, and the symbol stays ENLV. Form 6-K · SEC filing · Press release
Oct 19, 2026 ·
Restructuring Enlivex announced a cost reduction plan effective immediately, winding down non-clinical R&D and cutting its workforce by approximately 60%. The CEO's salary will fall 40% and other management salaries 20%, to focus on the Phase 2b Allocetra trial, with topline six-month data expected by mid-2027. Form 6-K · SEC filing · Press release
Sep 29, 2026 ·
Shareholder vote Enlivex will hold an Extraordinary General Meeting on October 14, 2026 for shareholders to vote on a 1-for-16 reverse share split of its ordinary shares and a related amendment to its Articles of Association. The Board recommends voting FOR. Form 6-K · SEC filing · Press release
Sep 25, 2026 ·
Earnings Enlivex reported Q2 2026 net income of $1,891,614 thousand versus a $1,868 thousand loss a year earlier, driven by a $1,862,461 thousand fair value gain on its digital assets purchase option. Total assets rose to $4,899,966 thousand from $2,326,998 thousand at year-end 2025. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Feb 2027 · Phase 2 · Recruiting · Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not ENLV's own candidates): Nivolumab, Tislelizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ENLV holds $5.5M in cash and short-term investments and burns about $3.9M/quarter from operations,
an estimated runway of 4.3 months at that rate (BioRadar estimate, not company guidance).
Share count 237,381,498 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ENLV picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENLV and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.